Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim prophylaxis for chemotherapy-related neutropenia in non-myeloid malignancies
ChiCTR2200060208Phase 4Not yet recruiting
- Sponsor
- Air Force Specialty Medical Center
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecapegfilgrastim in chemotherapy-induced neutropenia (CIN), sponsored by Air Force Specialty Medical Center. Primary endpoint: Myelosuppression grade. Planned start May 2022; status: not yet recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on ChiCTR2200060208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060208.